(GALE) Galenica Sante - Ratings and Ratios
Pharmacies, Medication, OTC, Distribution, IT
Description: GALE Galenica Sante
Galenica Sante AG is a healthcare service provider operating in Switzerland and internationally, with a presence in two main segments: Products & Care, and Logistics & IT. The Products & Care segment is involved in operating pharmacies under various brands, offering medication for home treatment, and developing healthcare services and products. The Logistics & IT segment provides pre-wholesale services, including storage and distribution, to pharmaceutical companies, as well as offering master data systems and management solutions for the healthcare market.
From a financial perspective, Galenica Sante AG has a market capitalization of approximately 4.4 billion CHF, indicating a substantial presence in the healthcare industry. The companys price-to-earnings ratio is around 24, suggesting a moderate valuation. The forward P/E ratio is slightly lower, indicating potential for growth. The return on equity is a robust 32.57%, indicating a strong ability to generate profits from shareholder equity.
To further analyze the companys performance, key performance indicators (KPIs) such as revenue growth, EBITDA margin, and debt-to-equity ratio can be considered. A review of these KPIs would provide insights into the companys operational efficiency, profitability, and financial leverage. For instance, a high EBITDA margin would indicate Galenicas ability to maintain profitability, while a low debt-to-equity ratio would suggest a healthy capital structure.
Additionally, Galenicas diversified business segments and its role in the healthcare industry position it for potential long-term growth. The companys ability to provide a range of services, from pharmacy operations to logistics and IT solutions, allows it to capitalize on various opportunities within the healthcare sector. As the healthcare industry continues to evolve, Galenicas adaptability and commitment to innovation will be crucial in driving its future success.
GALE Stock Overview
| Market Cap in USD | 5,238m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception |
GALE Stock Ratings
| Growth Rating | 66.9% |
| Fundamental | 78.0% |
| Dividend Rating | 51.2% |
| Return 12m vs S&P 500 | 1.96% |
| Analyst Rating | - |
GALE Dividends
| Dividend Yield 12m | 1.40% |
| Yield on Cost 5y | 1.90% |
| Annual Growth 5y | 4.10% |
| Payout Consistency | 93.4% |
| Payout Ratio | 29.8% |
GALE Growth Ratios
| Growth Correlation 3m | -19.5% |
| Growth Correlation 12m | 91.6% |
| Growth Correlation 5y | 89.6% |
| CAGR 5y | 6.95% |
| CAGR/Max DD 5y | 0.37 |
| Sharpe Ratio 12m | 1.44 |
| Alpha | 15.18 |
| Beta | -0.010 |
| Volatility | 15.08% |
| Current Volume | 74.9k |
| Average Volume 20d | 65.9k |
| Stop Loss | 82 (-3.1%) |
| Signal | -0.91 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (468.3m TTM) > 0 and > 6% of Revenue (6% = 460.4m TTM) |
| FCFTA 0.12 (>2.0%) and ΔFCFTA 6.71pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.91% (prev 4.97%; Δ -1.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 490.4m > Net Income 468.3m (YES >=105%, WARN >=100%) |
| Net Debt (106.2m) to EBITDA (606.9m) ratio: 0.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.41 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (49.9m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 10.03% (prev 9.15%; Δ 0.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 253.2% (prev 134.2%; Δ 119.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.20 (EBITDA TTM 606.9m / Interest Expense TTM 25.9m) >= 6 (WARN >= 3) |
Altman Z'' 4.30
| (A) 0.10 = (Total Current Assets 1.03b - Total Current Liabilities 731.7m) / Total Assets 3.07b |
| (B) 0.51 = Retained Earnings (Balance) 1.56b / Total Assets 3.07b |
| (C) 0.14 = EBIT TTM 420.3m / Avg Total Assets 3.03b |
| (D) 1.03 = Book Value of Equity 1.56b / Total Liabilities 1.52b |
| Total Rating: 4.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 78.00
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 8.08% = 4.04 |
| 3. FCF Margin 4.91% = 1.23 |
| 4. Debt/Equity 0.38 = 2.43 |
| 5. Debt/Ebitda 0.98 = 1.80 |
| 6. ROIC - WACC 19.66% = 12.50 |
| 7. RoE 32.57% = 2.50 |
| 8. Rev. Trend 12.78% = 0.64 |
| 9. Rev. CAGR 3.12% = 0.39 |
| 10. EPS Trend -23.58% = -0.59 |
| 11. EPS CAGR 10.65% = 1.07 |
What is the price of GALE shares?
Over the past week, the price has changed by +0.48%, over one month by -2.76%, over three months by -3.64% and over the past year by +18.76%.
Is Galenica Sante a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GALE is around 85.74 CHF . This means that GALE is currently overvalued and has a potential downside of 1.35%.
Is GALE a buy, sell or hold?
What are the forecasts/targets for the GALE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 83.8 | -0.9% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 92.9 | 9.8% |
GALE Fundamental Data Overview
Market Cap CHF = 4.21b (4.21b CHF * 1.0 CHF.CHF)
CCE Cash And Equivalents = 129.7m CHF (last quarter)
P/E Trailing = 21.8653
P/E Forward = 20.79
P/S = 1.044
P/B = 2.9066
Beta = 0.296
Revenue TTM = 7.67b CHF
EBIT TTM = 420.3m CHF
EBITDA TTM = 606.9m CHF
Long Term Debt = 539.7m CHF (from longTermDebt, last quarter)
Short Term Debt = 52.7m CHF (from shortTermDebt, last quarter)
Debt = 592.4m CHF (Calculated: Short Term 52.7m + Long Term 539.7m)
Net Debt = 106.2m CHF (from netDebt column, last quarter)
Enterprise Value = 4.67b CHF (4.21b + Debt 592.4m - CCE 129.7m)
Interest Coverage Ratio = 16.20 (Ebit TTM 420.3m / Interest Expense TTM 25.9m)
FCF Yield = 8.08% (FCF TTM 377.0m / Enterprise Value 4.67b)
FCF Margin = 4.91% (FCF TTM 377.0m / Revenue TTM 7.67b)
Net Margin = 6.10% (Net Income TTM 468.3m / Revenue TTM 7.67b)
Gross Margin = 10.03% ((Revenue TTM 7.67b - Cost of Revenue TTM 6.90b) / Revenue TTM)
Tobins Q-Ratio = 2.99 (Enterprise Value 4.67b / Book Value Of Equity 1.56b)
Interest Expense / Debt = 1.10% (Interest Expense 6.55m / Debt 592.4m)
Taxrate = 14.40% (from yearly Income Tax Expense: 30.9m / 214.6m)
NOPAT = 359.8m (EBIT 420.3m * (1 - 14.40%))
Current Ratio = 1.41 (Total Current Assets 1.03b / Total Current Liabilities 731.7m)
Debt / Equity = 0.38 (Debt 592.4m / last Quarter total Stockholder Equity 1.55b)
Debt / EBITDA = 0.98 (Net Debt 106.2m / EBITDA 606.9m)
Debt / FCF = 1.57 (Debt 592.4m / FCF TTM 377.0m)
Total Stockholder Equity = 1.44b (last 4 quarters mean)
RoA = 15.25% (Net Income 468.3m, Total Assets 3.07b )
RoE = 32.57% (Net Income TTM 468.3m / Total Stockholder Equity 1.44b)
RoCE = 21.25% (Ebit 420.3m / (Equity 1.44b + L.T.Debt 539.7m))
RoIC = 25.02% (NOPAT 359.8m / Invested Capital 1.44b)
WACC = 5.36% (E(4.21b)/V(4.80b) * Re(5.98%)) + (D(592.4m)/V(4.80b) * Rd(1.10%) * (1-Tc(0.14)))
Shares Correlation 5-Years: 60.0 | Cagr: 0.15%
Discount Rate = 5.98% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈292.8m ; Y1≈361.2m ; Y5≈616.3m
Fair Price DCF = 210.4 (DCF Value 10.48b / Shares Outstanding 49.8m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 12.78 | Revenue CAGR: 3.12%
Rev Growth-of-Growth: -19.24
EPS Correlation: -23.58 | EPS CAGR: 10.65%
EPS Growth-of-Growth: -61.10